Report overview
Hematological disorders deal with blood related diseases and generally affect the quantity or functionality of the cells or proteins present in the blood.
This report aims to provide a comprehensive presentation of the global market for Drugs and Diagnostics for Hematological Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs and Diagnostics for Hematological Disorders. This report contains market size and forecasts of Drugs and Diagnostics for Hematological Disorders in global, including the following market information:
Global Drugs and Diagnostics for Hematological Disorders Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Drugs and Diagnostics for Hematological Disorders market was valued at US$ 97320 million in 2022 and is projected to reach US$ 128670 million by 2029, at a CAGR of 4.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Some blood disorders result in the increase of the number of cells in blood such as anemia, leukopenia while other cause the number of blood cells to decrease such as leukocytosis and thrombocytosis. The modern approach of using point of care diagnostics, cytometry techniques in hematological disorder diagnosis have outpaced the traditional methods because they can be used even in the absence of healthcare personnel and in extreme conditions.
We surveyed the Drugs and Diagnostics for Hematological Disorders companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs and Diagnostics for Hematological Disorders Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Drugs and Diagnostics for Hematological Disorders Market Segment Percentages, by Type, 2022 (%)
Analyzers
Reagents
Global Drugs and Diagnostics for Hematological Disorders Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Drugs and Diagnostics for Hematological Disorders Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Drugs and Diagnostics for Hematological Disorders Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Drugs and Diagnostics for Hematological Disorders Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs and Diagnostics for Hematological Disorders revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Drugs and Diagnostics for Hematological Disorders revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abbot
Pfizer
Amgen
Beckman Coulter
Mindray
Roche
Biorad
Eli Lilly
Sysmex
Bristol-Myers
Siemens
Horbia
Nihon Kohden
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs and Diagnostics for Hematological Disorders, market overview.
Chapter 2: Global Drugs and Diagnostics for Hematological Disorders market size in revenue.
Chapter 3: Detailed analysis of Drugs and Diagnostics for Hematological Disorders company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs and Diagnostics for Hematological Disorders in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
